Scientific Reports · 2018 · 48 citations · 42 references
Life SciencesOncologyPharmacologyCancer PharmacologyDrug DiscoveryMetabolomicsCancer MetabolomicsMetabolite AnnotationMetabolite IdentificationMetabolite ProfilingNuclear Magnetic Resonance MetabolomicsPlant MetabolomicsAnticancer ActivityAnticancer Natural ProductsBioactive ConstituentsBioactive Plant CompoundsPharmacological ScreeningPlant Metabolite ProfilingSecondary Metabolite DiscoverySecondary Metabolites
Abstract The discovery of bioactive compounds from natural sources entails an extremely lengthy process due to the timescale and complexity of traditional methodologies. In our study, we used a rapid NMR based metabolomic approach as tool to identify secondary metabolites with anti-proliferative activity against a panel of human colorectal cancer cell lines with different mutation profiles. For this purpose, fourteen Fabaceae species of Mediterranean vegetation were investigated using a double screening method: 1 H NMR profiling enabled the identification of the main compounds present in the mixtures, whilst parallel biological assays allowed the selection of two plant extracts based on their strong anti-proliferative properties. Using high-resolution 2D NMR spectroscopy, putative active constituents were identified in the mixture and isolated by performing a bio-guided fractionation of the selected plant extracts. As a result, we found two active principles: a cycloartane glycoside and protodioscin derivative. Interestingly, these metabolites displayed a preferential anti-proliferative effect on colon cancer cell lines with an intrinsic resistance to anti-EGFR therapies. Our work provides an NMR-based metabolomic approach as a powerful and efficient tool to discover natural products with anticancer activities circumventing time-consuming procedures.
42
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +17
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad, Chong Sun, Sidong Huang et al. · Nature · 2012 · 2.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale, Rona Yaeger, Sebastijan Hobor et al. · Nature · 2012 · 1.9K citations · Full text
Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text
Medicine, Oncology, Pharmacology +17